Clinical Trials Logo

Dysentery clinical trials

View clinical trials related to Dysentery.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03038243 Withdrawn - Clinical trials for Shigella Sonnei Dysenteries

Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults

Start date: August 1, 2017
Phase: Phase 2
Study type: Interventional

This is a research study about an experimental (investigational) oral inactivated whole cell Shigella flexneri 2a killed vaccine (Sf2aWC) and an adjuvant called dmLT. Sf2aWC is a killed vaccine that is being made to prevent disease from Shigella., which causes bloody, watery diarrhea. An adjuvant is something that is added to a vaccine to make it work better. The purpose of the study is to see if the vaccine will protect people from Shigella infection with or without an adjuvant called dmLT. About 72 healthy adults, ages 18-45, will participate in this study. The study will compare 2 different vaccination groups and 1 control group. Volunteers have an equal chance to be in any of the 3 groups. Study procedures include: stool samples, blood samples and documenting side effects. Participants will be involved in study related procedures for about 6 months.

NCT ID: NCT02736539 Withdrawn - Traveler's Diarrhea Clinical Trials

Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea

Start date: April 15, 2017
Phase: Phase 3
Study type: Interventional

This study is designed as a randomized double-blinded treatment trial among travelers' to geographical areas with moderate-severe rates of traveler's diarrhea. Travelers will be randomized to receive CBS 2004 or masked placebo to be taken daily while traveling. The test article or placebo will be taken starting 7 days prior to travel.

NCT ID: NCT00875875 Withdrawn - Travelers' Diarrhea Clinical Trials

Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea

Rifaximin 600
Start date: June 2009
Phase: Phase 4
Study type: Interventional

The study will compare durations of diarrhea among subjects who report to clinic for treatment and who receive either: 1. standard rifaximin therapy at a dose of 200 mg three times a day for 3 days, OR 2. a single 600 mg dose of rifaximin daily for 3 days.